

DATE	TIME	***IDS*** PRO15050414
		<p>TITLE: Amantadine to Stimulate Wakefulness Following Post-Anoxic Encephalopathy (AWAKE) IRB#: PRO15050414</p> <p>PRINCIPAL INVESTIGATOR: Jon Rittenberger, MD CO-INVESTIGATORS: Clifton Callaway, MD; Cameron Dezfulian, MD; Ankur Doshi, MD; Jonathan Elmer, MD; Lillian Emlet, MD, Philip Empey, Pharm D; Frank Guyette, MD; Bradley Molyneaux, MD COORDINATOR: Sara DiFiore Phone: 412-864-2284</p> <p>FAX ORDER TO (412)647-9651 M-F 6:30A-3P and call 864-3270 to confirm receipt of fax After hours, FAX to main pharmacy @ (412)647-7222 and call 412-647-1035 to confirm</p> <p>PATIENT CONSENT SIGNED: YES or NO (circle one)</p> <p><u>STRATUM:</u> PCAC II with malignant EEG PCAC II without malignant EEG (circle one) PCAC III PCAC IV</p> <p>4-digit RANDOMIZATION NUMBER: _____</p> <p>DISPENSE: Amantadine 100mg/Placebo</p> <p>DOSE FORM TO DISPENSE: (circle one) 100mg/10ml oral liquid OR 100mg oral capsule</p> <p>DIRECTIONS: Take 100mg twice daily at 6AM and NOON for 7 days.</p> <p>PHYSICIAN SIGNATURE: _____ DATE: _____</p>

INVESTIGATIONAL DRUG SERVICE

PATIENT ENROLLMENT SHEET

Study Title: Amantadine to Stimulate Wakefulness Following Post-Anoxic Encephalopathy (AWAKE)

IRB#: PRO15050414

PI: Jon Rittenberger, MD

Patient Name: _____
 first mi last

Patient Address: _____

Patient Phone number: (_____) _____

Social Security Number: _____

Date of birth: _____

Allergies: _____

Patient signed informed consent on file: YES / NO(circle one)

Scheduled first day of therapy: _____

Enrollment completed by: _____

Phone number for questions: _____

Fax completed form to the IDS Office at 647-9651

Please call to IDS Office with any questions at 647-4958 or 647-3178 (pharmacists) or 647-9065 (technician)

Date	DRUG	DOSE MODIFICATION MODIFICATION	REASON
1) _____	_____	_____	_____
2) _____	_____	_____	_____